Insights into BRCA Cancer Predisposition from Integrated Germline and Somatic Analyses in 7632 Cancers

Abstract Background It is often assumed any cancer in a germline BRCA1 or BRCA2 (collectively termed BRCA) mutation carrier was caused by that mutation. It is also often assumed the occurrence of breast or ovarian cancer in an individual with a variant of uncertain significance (VUS) suggests the VUS is pathogenic. These assumptions have profound management implications for cancer patients and healthy individuals. Methods We compared the frequency of BRCA mutations, allele loss, and Signature 3 in 7632 individuals with 28 cancers and 1000 population controls. Because only increased frequency was the focus of the study, all statistical tests were one-sided. Results Individuals with breast or ovarian cancer had increased germline BRCA pathogenic mutation frequencies compared to controls (P = 1.0x10−10 and P = 1.4x10−34, respectively). There was no increase in other cancer types. Wild-type allele loss and Signature 3 were statistically significantly higher in breast and ovarian cancers with BRCA mutations compared with other cancers with BRCA mutations (P = 5.1x10−10 and P = 3.7x10−9) and cancers without BRCA mutations (P = 2.8x10−53 and P = 1.0x10−134). There was no difference between non-breast and non-ovarian cancers with BRCA mutations and cancers without BRCA mutations. Allele loss and Signature 3 were statistically significantly higher in breast and ovarian cancers in individuals with BRCA pathogenic mutations compared to those with VUS (P = 3.8x10−17 and P = 1.6x10−8) or benign variants (P = 1.2x10−28 and P = 2.2x10−10). There was no difference between individuals with BRCA VUS and those with benign variants. Conclusions These data show that non-breast and non-ovarian cancers in individuals with germline BRCA pathogenic mutations are often not causally related to the mutation and that BRCA VUS are highly unlikely to be pathogenic. These results should reduce inappropriate management of germline BRCA information.

[1]  Raymond M. Moore,et al.  Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer , 2018, JAMA.

[2]  Annette Lee,et al.  Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations , 2018, Human mutation.

[3]  A. Naik,et al.  Risk management decisions in women with BRCA1 and BRCA2 mutations. , 2018, American journal of surgery.

[4]  Steven J. M. Jones,et al.  Pathogenic Germline Variants in 10,389 Adult Cancers. , 2018, Cell.

[5]  G. Tortora,et al.  The development of PARP as a successful target for cancer therapy , 2018, Expert review of anticancer therapy.

[6]  D. Easton,et al.  Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia , 2017, Journal of Medical Genetics.

[7]  S. E. Stanley,et al.  Germline Mutations in DNA Repair Genes in Lung Adenocarcinoma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  Yate-Ching Yuan,et al.  Genetic Gastric Cancer Susceptibility in the International Clinical Cancer Genomics Community Research Network. , 2017, Cancer genetics.

[9]  E. Lander,et al.  A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.

[10]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[11]  R. Jagsi,et al.  Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[13]  Hajime Uno,et al.  Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Vijai Joseph,et al.  Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  David M. Thomas,et al.  Monogenic and polygenic determinants of sarcoma risk: an international genetic study. , 2016, The Lancet. Oncology.

[16]  K. Nathanson,et al.  Population Frequency of Germline BRCA1/2 Mutations. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Nazneen Rahman,et al.  OpEx - a validated, automated pipeline optimised for clinical exome sequence analysis , 2016, Scientific Reports.

[18]  Ahmet Zehir,et al.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.

[19]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[20]  Ann M. Bailey,et al.  Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Julian Peto,et al.  Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. , 2016, Human molecular genetics.

[22]  S. Seal,et al.  Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients , 2016, Scientific Reports.

[23]  Dong Liang,et al.  BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. , 2016, Journal of the National Cancer Institute.

[24]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[25]  S. Seal,et al.  The ICR1000 UK exome series: a resource of gene variation in an outbred population , 2015, F1000Research.

[26]  F. Couch,et al.  BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[28]  Amar S. Ahmad,et al.  Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960 , 2015, British Journal of Cancer.

[29]  B. Arun,et al.  Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian , 2022 .

[30]  Brian Craft,et al.  The Cancer Genomics Hub (CGHub): overcoming cancer through the power of torrential data , 2014, Database J. Biol. Databases Curation.

[31]  Andrey Alexeyenko,et al.  Distinguishing between driver and passenger mutations in individual cancer genomes by network enrichment analysis , 2014, BMC Bioinformatics.

[32]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[33]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[34]  Gail P Jarvik,et al.  Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: Variant reclassification and surgical decisions , 2011, Genetics in Medicine.

[35]  W. Foulkes,et al.  BRCA1 and BRCA2: 1994 and beyond , 2004, Nature Reviews Cancer.

[36]  S. Sharan,et al.  Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model. , 2003, Human molecular genetics.

[37]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[38]  Cancer Risks in BRCA 2 Mutation Carriers The Breast Cancer Linkage Consortium , 1999 .

[39]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.